February 1, 2017
Kyowa Hakko Kirin said on January 31 that KHK7580, the company’s hoped-to-be successor to Regpara (cinacalcet), showed non-inferiority versus the older drug in patients with secondary hyperparathyroidism on hemodialysis in Japan. The randomized, double-blind study examined the efficacy and safety...read more